Halozyme Therapeutics | Betriebsaufwand



Operating Expenses Veränderung Datum
Acadia Pharmaceuticals USD 106.1M 112.66M 2024-12
Agios Pharmaceuticals USD 135.77M 1.11B 2024-12
Alnylam Pharmaceuticals USD 698.32M 120.5M 2024-12
Amarin USD 67.47M 549K 2024-09
Amgen USD 6.78B 401M 2024-12
Baxter International USD 3.19B 644M 2024-12
Cytokinetics USD 155.97M 14.7M 2024-12
DBV Technologies USD 31.4M 3.6M 2024-09
Eli Lilly USD 8.38B 1.53B 2024-12
Halozyme Therapeutics USD 122.51M 4.38M 2024-12
Indivior 213M 218M 2024-09
Intra Cellular Therapies USD 228.42M 14.2M 2024-12
Ionis Pharmaceuticals USD 337.4M 54.93M 2024-12
MannKind USD 63.68M 11.62M 2024-12
Pfizer USD 18.17B 5.63B 2024-12
United Therapeutics USD 378.2M 27.6M 2024-12



Halozyme Therapeutics Betriebsaufwand - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Mar 2025.